research Selective Inhibition of JAK3 Signaling Is Sufficient to Reverse Alopecia Areata
Blocking JAK3 signaling can reverse hair loss from alopecia areata.
Search
for
Sort by
Research
30 / 272 results
research Discovery Of A Novel And Highly Selective JAK3 Inhibitor As A Potent Hair Growth Promoter
MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Selectively Targeting JAK1 or JAK3 Pathway Is Sufficient to Reverse Alopecia Areata
Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
research Effectiveness of OR-101, a Next Generation Highly Selective JAK3 Inhibitor, in a Humanized Murine Model of Alopecia Areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Ideal JAK Inhibitor for Alopecia Areata: Baricitinib, Tofacitinib, Ritlecitinib, or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
No single ideal JAK inhibitor for alopecia areata has been determined; JAK3 inhibitors may be promising with fewer side effects.
research Efficacy of Topical Tofacitinib in Promoting Hair Growth in Non-Scarring Alopecia: Possible Mechanism via VEGF Induction
Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.
research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions
New treatments targeting T-cell pathways are needed for better alopecia areata management.
research Molecular Profiling of Frontal Fibrosing Alopecia Reveals TH1 and JAK-STAT Up-Regulation with No Suppression of Hair Keratins
Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.
research Tofacitinib Treatment in Patients With Active COVID-19 Infection
Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.
research In-Silico Screening of ATP-Competitive Inhibitory Activities of Phytochemicals Against Janus Kinase 3 and Its In-Vitro Evaluation
Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
research Cedrol in Ginger (Zingiber Officinale) as a Promising Hair Growth Drug: The Effects of Oral and External Administration on Hair Regeneration and Its Mechanism
Cedrol from ginger can promote hair growth when taken orally.
research Use of Ritlecitinib for the Treatment of Alopecia Areata
Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
research Advances In The Mechanism And New Therapies Of Alopecia Areata
New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
research Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the Allegro Phase 2b/3 Study
Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research JAK Inhibitors: New Players in the Field of Immune-Mediated Diseases Beyond Rheumatoid Arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies
Animal models have helped understand hair loss from alopecia areata and find new treatments.
research Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Extensive Alopecia Areata Is Reversed by IL-12/IL-23p40 Cytokine Antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research The Effect of JAK Inhibitor on Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
Ruxolitinib may help treat hair loss by reducing inflammation, promoting hair growth signals, and protecting hair follicle immunity.
research Application of Baricitinib in Dermatology
Baricitinib shows promise as a new treatment for certain skin conditions like alopecia areata.
research Safety of Janus Kinase Inhibitors in Patients with Alopecia Areata: A Systematic Review
JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
research Improvement of Psoriasis, Psoriatic Arthritis, and Alopecia Universalis During Treatment with Tofacitinib: A Case Report
Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
research An Open-Label Pilot Clinical Trial of the JAK Inhibitor Tofacitinib for Alopecia Areata
Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.
research Effect of Tofacitinib on the Expression of Noggin/BMP-4 and Hair Growth Stimulation in Mice
Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.